⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 20, 2024Dermatitis

Efficacy, Safety, and Early Relapse After Cessation of Upadacitinib Versus Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Real-World Study in China

Jiling Zhu Hanwen Wu Yahui Ye Qiuyang Xu Junyi Shao Zicheng Bai Yiwen Zhou Zhenyan Li Jingjing Liu Zhiming Li

View at Publisher

Ask AI

Bookmark

Share

Abstract

The efficacy and safety of upadacitinib and dupilumab for atopic Dermatitis® (AD) in adolescent patients have been proven in clinical trials. However, few daily practice studies comparing agents have been conducted in this patient population.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhu et al. (2024) studied this question.

synapsesocial.com/papers/68e5b8a1b6db6435875512ff https://doi.org/10.1089/derm.2024.0014

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1734 - Efficacy and safety of upadacitinib vs dupliumab in adults and adolescents with moderate-to-severe atopic dermatitis: results of an open-label, efficacy assessor-blinded head-to-head phase 3b/4 study (Level Up)2024 · 2 citations
2Treatment of atopic dermatitis with upadacitinib: adcare single center experience2024 · 7 citations
3Upadacitinib in daily practice for refractory atopic dermatitis in adolescents: a case series of the BioDay registry2025 · 1 citations
4Real-World Evidence of Upadacitinib in Atopic Dermatitis after Inadequate Response or Intolerance to Dupilumab: The CAN UpTIMISE StudyObservational Study · 2026
5Upadacitinib in Adolescents With Moderate to Severe Atopic DermatitisRCT · 2024 · 17 citations

More related papers

Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP)2026
Upadacitinib in children under 12 years with dupilumab-refractory severe atopic dermatitis: a real-world case series2026
Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study2024

More from Dermatitis

Validation of Head and Neck EASI Severity Strata Against vIGA-AD in Atopic DermatitisFri,
Atopic Dermatitis and Emotional and Behavioral Outcomes in Infants and Toddlers: A U.S. Population-Based StudyMon,